{"prompt": "['Some patients may develop a suspicious recurrence that leads quickly to death without the', 'possibility of confirming relapse of disease. Efforts should be made to obtain an autopsy', 'report in such patients.', '4.5.10', 'Cardiac Function', 'Prior to study enrolment, patients must have an assessment for history of cardiac events, a', 'physical examination, an ECG (per standard institutional methods), and an LVEF', 'assessment (by ECHO or MUGA) to exclude any cardiac condition that would render them', 'ineligible for participation in this trial. Cardiac function will be assessed locally according to', 'the schedule of activities (see Appendix 1).', 'All patients must have an LVEF 55% by ECHO or MUGA scan in order to be eligible for', 'the study. The same LVEF evaluation method should be used throughout the study for each', 'patient and should be performed and assessed by the same assessor if possible. Results of', 'LVEF assessments must be reviewed prior to study treatment administration on the', 'scheduled visit day.', 'Investigators must be aware of local institutional regulations regarding the maximum', 'allowable frequency of repeat MUGA scans. The repeated administration of radioisotopes is', 'limited in some nuclear medicine laboratories, and patients in this study require LVEF', 'assessment on more than four occasions within one year.', '4.5.11', 'Laboratory Samples', \"Samples for the following laboratory tests will be sent to the study site's local laboratory for\", 'analysis:', 'Haematology: haemoglobin, total white blood count (WBC), ANC / neutrophil count,', 'platelet count.', 'Limited biochemistry: alkaline phosphatase; AST; ALT; lactate dehydrogenase (LDH);', 'total bilirubin; creatinine. Albumin should be measured at Screening for determining patient', 'eligibility. Bilirubin fractions (direct and indirect) must be included if total bilirubin is', 'greater than ULN.', 'Pregnancy test', 'For all women of childbearing potential (see Section 4.1.1), pregnancy tests must be', 'performed via serum \u00df-human chorionic gonadotropin (HCG) at baseline and via urine', 'tests thereafter according to Appendix 1 until seven months after discontinuation of study', 'treatment. Any positive urine pregnancy test must be confirmed with a serum \u00df-HCG', 'test. During the study treatment periods, pregnancy test results must be available prior to', 'study treatment administration.', 'For women who are not of childbearing potential, documentation must be present in', 'medical history confirming that the patient is not of childbearing potential.', '4.5.12', 'Patient Reported Outcomes', 'Patient reported outcomes will be collected via paper questionnaires. All questionnaires', 'must be completed in their entirety at the specified timepoints during the study (Appendix 1).', 'The questionnaires will be translated into the local language as appropriate.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '53 / Protocol MO40628, Version 12']['4.5.12.1', 'Patient Preference Questionnaire', 'The PPQ will be completed by each patient immediately after completion of treatment', 'administration at the scheduled timepoint. Please refer to Appendix 1 for instructions', 'regarding when patients who prematurely discontinue study treatment should complete the', 'PPQ.', '4.5.12.2', 'Therapy Administration Satisfaction Questionnaires', 'Patient assessed satisfaction with P+H IV and pertuzumab and trastuzumab FDC SC will be', 'evaluated using the TASQ-IV and TASQ-SC, respectively. Each TASQ will be completed by', 'the patient immediately after completion of treatment administration at the scheduled', 'timepoint. Please refer to Appendix 1 for instructions regarding when patients who switch', 'study treatment due to lack of tolerance should complete each TASQ.', '4.5.12.3', 'European Organisation for Research and Treatment of Cancer Quality', 'of Life Questionnaire (EORTC QLQ-C30)', 'Patient reported HRQoL will be assessed via the EORTC QLQ-C30 administered at', 'specified timepoints throughout the study including during the Follow-up Period.', 'To ensure instrument validity and that data standards meet health authority requirements,', 'the EORTC QLQ-C30 will be self-administered before the patient and clinician receives any', 'information on disease status and prior to treatment administration on the scheduled visit', 'day.', '4.5.13', 'Healthcare Professional Reported Outcomes', '4.5.13.1', 'Healthcare Professional Questionnaire', 'Healthcare professional reported perception of time and resource use associated with', 'pertuzumab and trastuzumab FDC SC will be assessed via two HCPQs (see Appendix 3).', 'One HCPQ (HCPQ-Treatment Room) will be completed by an HCP involved in treatment', 'preparation and/or administration in the treatment room where study drugs are administered.', 'The other HCPQ (HCPQ-Drug Preparation Area) will be completed by an HCP involved in', 'study drug preparation. Please refer to each HCPQ in Appendix 3 for personnel qualifying as', 'HCPs for each questionnaire. The HCPQs will be completed by the HCP after preparation', 'and/or administration of the study treatment at each scheduled time point (see Appendix 1).', '4.6', 'TREATMENT, PATIENT, STUDY, AND SITE DISCONTINUATION', '4.6.1', 'Study Treatment Discontinuation', 'Patients must permanently discontinue study treatment if they experience any of the', 'following:', 'Any medical condition that the investigator or Sponsor determines may jeopardize the', \"patient's safety if he or she continues to receive study treatment\", 'Investigator or Sponsor determination that treatment discontinuation is in the best', 'interest of the patient', 'Pregnancy', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '54 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}